As a group, equities analysts expect that Bristol-Myers Squibb will post 7.43 earnings per share for the current fiscal year.

Source: https://www.etfdailynews.com/2023/09/30/cornerstone-advisory-llc-sells-392-shares-of-bristol-myers-squibb-nysebmy/

Atlantic Securities increased their price target on Bristol-Myers Squibb from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, February 3rd.

Source: https://www.americanbankingnews.com/2023/05/01/765-shares-in-bristol-myers-squibb-nysebmy-purchased-by-glass-jacobson-investment-advisors-llc.html

Bank of America upped their price target on Bristol-Myers Squibb from $82.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, April 21st.

Source: https://www.americanbankingnews.com/2023/06/23/central-bank-trust-co-has-557000-position-in-bristol-myers-squibb-nysebmy.html

Based on data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $63.

Source: https://www.etfdailynews.com/2023/12/02/bryn-mawr-capital-management-llc-buys-2542-shares-of-bristol-myers-squibb-nysebmy/

Berenberg Bank lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and decreased their target price for the company from $82.00 to $76.00 in a research note on Wednesday, September 14th.

Source: https://www.americanbankingnews.com/2023/01/05/capital-investment-counsel-inc-trims-stake-in-bristol-myers-squibb-nysebmy.html

Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Scotia Capital Inc.

Source: https://www.etfdailynews.com/2023/10/28/bristol-myers-squibb-nysebmy-shares-purchased-by-scotia-capital-inc/

Catalyst Financial Partners LLC boosted its holdings in shares of Bristol-Myers Squibb by 2.5% in the first quarter.

Source: https://www.americanbankingnews.com/2023/06/23/central-bank-trust-co-has-557000-position-in-bristol-myers-squibb-nysebmy.html

Coppell Advisory Solutions Corp. bought a new position in Bristol-Myers Squibb during the 4th quarter valued at $31,000.

Source: https://www.etfdailynews.com/2023/12/09/bristol-myers-squibb-nysebmy-shares-sold-by-kolinsky-wealth-management-llc/

Envestnet Asset Management Inc. increased its position in shares of Bristol-Myers Squibb by 193.4% in the first quarter.

Source: https://www.etfdailynews.com/2023/09/30/cornerstone-advisory-llc-sells-392-shares-of-bristol-myers-squibb-nysebmy/

Finally, Live Oak Investment Partners bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $33,000.

Source: https://www.etfdailynews.com/2023/12/29/hunter-perkins-capital-management-llc-has-5-47-million-position-in-bristol-myers-squibb-nysebmy/

Finally, McClarren Financial Advisors Inc. bought a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at $41,000.

Source: https://www.americanbankingnews.com/2023/03/25/altus-wealth-group-llc-makes-new-investment-in-bristol-myers-squibb-nysebmy.html

Hennessy Advisors Inc. decreased its stake in shares of Bristol-Myers Squibb () by 2.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC.

Source: https://www.dailypolitical.com/2023/12/28/bristol-myers-squibb-nysebmy-position-lowered-by-hennessy-advisors-inc.html

Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC Therapeutics, and Organogenesis are the leading players in the cell and gene therapy market.

Source: https://www.prnewswire.com/news-releases/germany-cell-and-gene-therapy-market---focused-insights-2023-2028-sector-to-reach-3-44-billion-by-2028-at-a-40-cagr-301784069.html

On average, equities analysts predict that Bristol-Myers Squibb will post 7.6 earnings per share for the current year.

Source: https://www.etfdailynews.com/2023/01/09/assenagon-asset-management-s-a-has-6-35-million-holdings-in-bristol-myers-squibb-nysebmy/

Principal Street Partners LLC cut its holdings in shares of Bristol-Myers Squibb () by 4.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission.

Source: https://www.etfdailynews.com/2023/12/13/bristol-myers-squibb-nysebmy-shares-sold-by-principal-street-partners-llc/

Specifically, Bristol-Myers Squibb is exposed to potential IRA price negotiation pressures for its major drugs including Eliquis, Opdivo, and Orencia; although I do not yet model IRA-driven price pressure as I would like to await further developments.

Source: https://seekingalpha.com/article/4637617-bristol-myers-squibb-looks-grossly-overvalued-loe-dragging-topline?source=feed_all_articles

UBS Group reaffirmed a “neutral” rating and set a $60.00 target price (down previously from $70.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 20th.

Source: https://www.etfdailynews.com/2023/11/12/1st-source-bank-cuts-stock-holdings-in-bristol-myers-squibb-nysebmy/

William Blair downgraded Bristol-Myers Squibb from an “outperform” rating to a “market perform” rating in a research report on Friday, October 27th.

Source: https://www.etfdailynews.com/2023/12/23/bristol-myers-squibb-nysebmy-shares-sold-by-relyea-zuckerberg-hanson-llc/